Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Recruiting 2

Sponsor Class

NIH 1NETWORK 1

Study Type

Interventional 2Observational 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Teratoma 1Neoplasms, Germ Cell and Embryonal 1Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8 1Endodermal Sinus Tumor 1Carcinoma, Embryonal 1

Interventions

Specimen Handling 415Magnetic Resonance Spectroscopy 332pembrolizumab 261Biopsy 227Carboplatin 216Cisplatin 179Cyclophosphamide 174Paclitaxel 148Nivolumab 135Gemcitabine 130Radiotherapy 120Dexamethasone 105Bevacizumab 101fludarabine 95Radiation 94Fluorouracil 93Pemetrexed 88Doxorubicin 88Docetaxel 83Rituximab 82venetoclax 81durvalumab 81Oxaliplatin 81Leucovorin 76atezolizumab 68Lenalidomide 66Capecitabine 66Prednisone 65Etoposide 64Vincristine 62

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Bleomycin × 30 days × Clear all
NCT05675410 2026-05-27

A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab

National Cancer Institute (NCI)

Phase 3 Recruiting
1,875 enrolled
Lymphoid

Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8

NCT03067181 2026-05-05

Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors

Children's Oncology Group

Phase 3 Recruiting
1,780 enrolled

Neoplasms, Germ Cell and Embryonal, Teratoma, Carcinoma, Embryonal, Endodermal Sinus Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡